Peter Nicholas Christie, DO | |
1215 W Baltimore Pike, Suite 13, Media, PA 19063-5540 | |
(610) 565-1919 | |
(610) 566-8971 |
Full Name | Peter Nicholas Christie |
---|---|
Gender | Male |
Speciality | Family Practice |
Experience | 40 Years |
Location | 1215 W Baltimore Pike, Media, Pennsylvania |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1205805413 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | OS005633L (Pennsylvania) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Crozer Chester Medical Center | Upland, PA | Hospital |
Riddle Memorial Hospital | Media, PA | Hospital |
Bryn Mawr Hospital | Bryn mawr, PA | Hospital |
Mailing Address | Practice Location Address |
---|---|
Peter Nicholas Christie, DO 1215 W Baltimore Pike, Suite 13, Media, PA 19063-5540 Ph: (610) 565-1919 | Peter Nicholas Christie, DO 1215 W Baltimore Pike, Suite 13, Media, PA 19063-5540 Ph: (610) 565-1919 |
News Archive
A three-year follow-up study of patients in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial revealed that increased mortality among patients with advanced chronic hepatitis C who received long-term peginterferon therapy was attributed to non-liver related causes and occurred primarily in patients with bridging fibrosis. No pattern to this excess mortality was evident to researchers, but deaths were unrelated to the peginterferon treatment. Full findings are published in the April issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases (AASLD).
Valeant Pharmaceuticals International, Inc. and GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has approved Potiga Tablets, a potassium channel opener, as adjunctive treatment of partial-onset seizures in patients aged 18 years and older.
UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect.
Medical advancements that extend the lives of patients with cancer, heart failure and other serious chronic diseases have created another need: more clinicians skilled in specialized care for people with terminal illnesses.
› Verified 8 days ago
Sabeena Shafi Fazili, M.D Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1068 W Baltimore Pike, Media, PA 19063 Phone: 610-566-9400 Fax: 610-627-4230 | |
Susan Kirchdoerffer, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1098 W Baltimore Pike, Suite 3101, Media, PA 19063 Phone: 610-891-9277 Fax: 610-891-7778 | |
Dr. Maureen Buckley, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1088 W Baltimore Pike Ste 2506, Media, PA 19063 Phone: 484-227-8175 Fax: 484-227-2130 | |
Dr. William Joseph Strowhouer, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 100 Granite Dr, Suite 207, Media, PA 19063 Phone: 610-566-8885 Fax: 610-566-7196 | |
Dr. Trina L Bradburd, D. O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1098 W Baltimore Pike, Suite 3311, Media, PA 19063 Phone: 610-565-7810 Fax: 610-565-0546 | |
Michele Lee Boornazian, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1098 W Baltimore Pike, Suite 3101 Outpatient Pavilion, Media, PA 19063 Phone: 610-891-9277 Fax: 610-891-7778 |